Combined Salvianolic Acid B and Ginsenoside Rg1 Exerts Cardioprotection against Ischemia/Reperfusion Injury in Rats.
Lack of pharmacological strategies in clinics restricts the patient prognosis with myocardial ischemia/reperfusion (I/R) injury. The aim of this study was to evaluate the cardioprotection of combined salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1) against myocardial I/R injury and further investigate the underlying mechanism. I/R injury was induced by coronary artery ligation for Wistar male rats and hypoxia/reoxygenation injury was induced on H9c2 cells. Firstly, the best ratio between SalB and Rg1was set as 2:5 based on their effects on heart function detected by hemodynamic measurement. Then SalB-Rg1 (2:5) was found to maintain mitochondrial membrane potential and resist apoptosis and necrosis in H9c2 cell with hypoxia/reoxygenation injury. Companying with same dose of SalB or Rg1 only, SalB-Rg1 showed more significant effects on down-regulation of myocardial infarct size, maintenance of myocardium structure, improvement on cardiac function, decrease of cytokine secretion including TNF-α, IL-1β, RANTES and sVCAM-1. Finally, the SalB-Rg1 improved the viability of cardiac myocytes other than cardiac fibroblasts in rats with I/R injury using flow cytometry. Our results revealed that SalB-Rg1 was a promising strategy to prevent myocardial I/R injury.
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Yanping
Y
Deng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Min
M
Yang
Shenyang Pharmaceutical University, Wenhua Road #103, Shenyang, 110016, China.
Feng
F
Xu
Department of Medicinal Chemistry School of Pharmacy, Fudan University, Shanghai, 200237, China.
Qian
Q
Zhang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China; Shenyang Pharmaceutical University, Wenhua Road #103, Shenyang, 110016, China.
Qun
Q
Zhao
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Haitao
H
Yu
Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Defang
D
Li
Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Ge
G
Zhang
Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Aiping
A
Lu
Takarazuka University of Medical and Health Care, Hanayashiki-Midorigaoka, Takarazuka-city, 6660162, Japan.
Kenka
K
Cho
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China; Shenyang Pharmaceutical University, Wenhua Road #103, Shenyang, 110016, China.
Fukang
F
Teng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China; Shenyang Pharmaceutical University, Wenhua Road #103, Shenyang, 110016, China.
Peng
P
Wu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Linlin
L
Wang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Wanying
W
Wu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Xuan
X
Liu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
De-An
DA
Guo
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Baohong
B
Jiang
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001572:Benzofurans / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D018946:Chemokine CCL5 / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D004359:Drug Therapy, Combination / Q000379:methods; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D036145:Ginsenosides / Q000494:pharmacology*; D053583:Interleukin-1beta / Q000378:metabolism; D008297:Male; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D009336:Necrosis / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism; D053630:Depsides
D001572:Benzofurans; D002316:Cardiotonic Agents; D018946:Chemokine CCL5; D036145:Ginsenosides; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1; C076944:salvianolic acid B; D053630:Depsides; C035054:ginsenoside Rg1